A5036706022- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Breast Cancer Treatment Studies
- Lung Cancer Research Studies
- Neutropenia and Cancer Infections
- Immune Response and Inflammation
- Breast Lesions and Carcinomas
- Lung Cancer Treatments and Mutations
- Cancer Risks and Factors
- HER2/EGFR in Cancer Research
- Estrogen and related hormone effects
- Melanoma and MAPK Pathways
- Cancer, Lipids, and Metabolism
- Cancer Research and Treatments
- Metabolism, Diabetes, and Cancer
- Cancer, Stress, Anesthesia, and Immune Response
- Cutaneous Melanoma Detection and Management
- Cancer Genomics and Diagnostics
- Mycobacterium research and diagnosis
- Cancer-related Molecular Pathways
- BRCA gene mutations in cancer
- Nonmelanoma Skin Cancer Studies
- CAR-T cell therapy research
Rabin Medical Center
2014-2023
Tel Aviv University
2012-2023
Hôpital Lyon Sud
2000-2023
Centre Hospitalier René-Dubos
2000-2023
Hôpital Saint-Antoine
2000-2023
Sorbonne Université
2000-2023
PURPOSE: In a previous study of treatment for advanced colorectal cancer, the LV5FU2 regimen, comprising leucovorin (LV) plus bolus and infusional fluorouracil (5FU) every 2 weeks, was superior to standard North Central Cancer Treatment Group/Mayo Clinic 5-day 5FU/LV regimen. This phase III investigated effect combining oxaliplatin with LV5FU2, progression-free survival as primary end point. PATIENTS AND METHODS: Four hundred twenty previously untreated patients measurable disease were...
In a previous study of treatment for advanced colorectal cancer, the LV5FU2 regimen, comprising leucovorin (LV) plus bolus and infusional fluorouracil (5FU) every 2 weeks, was superior to standard North Central Cancer Treatment Group/Mayo Clinic 5-day 5FU/LV regimen. This phase III investigated effect combining oxaliplatin with LV5FU2, progression-free survival as primary end point.
Smoking is associated with an increased incidence of hormone receptor positive breast cancer. Data regarding worse cancer outcome in smokers are accumulating. Current literature the impact smoking on characteristics limited. We evaluated and outcome.This was a retrospective single center study. All women diagnosed from 4/2005 through 3/2012 treated our institute for early, estrogen positive, human epidermal growth factor 2 (HER2) negative cancer, whose tumors were sent Oncotype DX analysis...
Cutaneous squamous cell carcinoma (cSCC) is the second most common non-melanoma skin cancer worldwide. It usually treated surgically, with very high cure rates. However, in 3%-7% of cases, cSCC metastasizes to lymph nodes or distant organs. Many affected patients are elderly comorbidities who not candidates for standard-of-care curative-intent treatment surgery and/or radio-/chemotherapy. Immune checkpoint inhibitors, which target programmed death protein 1 (PD-1) pathways, have recently...
This prospective, nonrandomized study evaluates 4 schedules of granulocyte colony-stimulating factor (G-CSF) for patients with breast cancer receiving adjuvant dose-dense chemotherapy regarding febrile neutropenia, treatment delays, and costs.Two hundred thirty-one were enrolled to receive G-CSF schedules: filgrastim (300 mcg) days 3 10 [n = 84 (36.4%) group A]; 7 26 (11.3%) B]; 5, 7, 9, 11 64 (27.7%) C], or pegfilgrastim (6 mg) on day 2 [n=57 (24.6%) D].Thirteen hospitalized due 14 episodes...
Abstract Background: Tilsotolimod, an investigational Toll-like receptor 9 (TLR9) agonist, modulates the tumor immune microenvironment and has single-agent antitumor activity in preclinical models. The ILLUMINATE-101 phase 1b study (NCT03052205) explored safety, efficacy, effects of intratumoral tilsotolimod multiple solid tumors. Methods: Adults with a histologically- or cytologically-confirmed diagnosis cancer not amenable to curative therapies received 8, 16, 23, 32 mg into single lesion...
Four cycles of docetaxel/cyclophosphamide (DC) resulted in superior survival than doxorubicin/cyclophosphamide the treatment early breast cancer. The original study reported a 5% incidence febrile neutropenia (FN) recommending prophylactic antibiotics with no granulocyte colony-stimulating factor (G-CSF) support. worldwide adoption this protocol yielded several reports on substantially higher rates FN events. We explored use growth (GF) support days 8 and 12 cycle DC protocol.Our included...
Abstract Background In the literature, there are minimal data for treatment of grade 2 or 3 morbilliform/atypical target lesion rashes secondary to sorafenib vemurafenib given patients with advanced stage cancer. This poses a dilemma clinicians, particularly in neoplastic disease whom other optional treatments limited. Methods The cohort included on all attending dermato‐oncological clinic at tertiary medical center that presented 2011–2014 widespread rash following vemurafenib. All were...
Purpose . To evaluate the associations between metformin, insulin, statins, and levothyroxine breast cancer characteristics outcome. Methods Retrospective chart review of patients treated in our institute for early estrogen receptor (ER) positive, human epidermal growth factor 2 negative cancer, whose tumors were sent to Oncotype DX (ODX) analysis. Patients grouped according medications usage during time diagnosis. Each group was compared rest study population. Results The cohort included...
<b><i>Purpose:</i></b> To evaluate the association between angiotensin receptor blocker (ARB) usage and breast cancer characteristics outcomes. <b><i>Methods:</i></b> All patients who were treated in our institute for estrogen receptor-positive, human epidermal growth factor 2-negative early April 2005 March 2012 whose tumors sent Oncotype-DX analysis included. Medical records retrospectively reviewed. Data regarding ARB retrieved. Usage of...
Background . Our previous study of pulmonary function in 34 patients with early breast cancer without preexisting lung disease showed that anthracycline- and taxane-based adjuvant dose-dense chemotherapy (DDC) caused a significant 16.4% mean reduction carbon monoxide diffusing capacity (DLCO). The present reports the oncological outcomes these on long-term follow-up. Patients methods primary endpoint was DLCO measured by test (PFT) performed at median 27 months after DDC (range, 8–97) 25...
Despite the growing number of clinical trials assessing preoperative systemic chemotherapy (PST) for locally advanced breast cancer, optimal regimen has still to be defined.This was evaluate toxicity, operability rate, pathological response rate and disease-free overall survival associated with a PST consisting sequential administration single agents according individual tumor response.Medical files were reviewed 102 consecutive patients cancer treated in 2000-2007 neoadjuvant doxorubicin...
Abstract Background: Smoking is associated with an increased incidence of hormone receptor positive breast cancer. Data regarding worse cancer outcome in smokers are accumulating. Current literature the impact smoking on characteristics limited. The aim this study was to evaluate and estrogen positive, human epidermal growth factor 2 (HER2) negative early Methods: This a retrospective single center study. All patients diagnosed from 4/2005 through 3/2012 treated our institute for early, HER2...
Abstract Background Combination of pertuzumab, trastuzumab and chemotherapy is standard care for first-line treatment patients with human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer. Most randomized studies used combination taxanes anti HER2 targeted as 1st line treatment. The vinorelbine, pertuzumab has shown anti-tumor activity in a phase trial. No trials have compared outcomes between vinorelbine to taxane trastuzumab. Methods We retrospectively evaluated...
564 Background: In about 10% of breast cancer (BC) cases, a genetic mutation in the BRCA1/2 genes can be found. BCs associated with BRCA2 mutations present positive estrogen receptor (ER) status 50% all whereas BRCA1 are more aggressive and likely to ER-negative. Oncotype profiling has become standard care predict recurrence benefit from chemotherapy ER BC. The role Oncotype-DX BRCA mutation-carriers is not clear. Our primary end-point compare RS distribution carriers that General Population...
e12000 Background: Data regarding the impact of antihypertensive medications on breast cancer are inconsistent. We evaluated association between tumor characteristics and outcome for patients with estrogen receptor (ER) positive, human epidermal growth factor 2 (HER2) negative early cancer, whose tumors were sent to Oncotype DX analysis. Methods: This was a retrospective, single center study. Patients' Charts reviewed demographics, clinicopathological parameters, chronic medications,...